Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: Lessons learned from Pompe disease

导出原文传递

翻译打印收藏纠错

作者： Banugaria,S.G. ^[1] ; Prater,S.N. ^[2] ; McGann,J.K. ^[3] ; Feldman,J.D. ^[4] ; Tannenbaum,J.A. ^[5] ; Bailey,C. ^[6] ; Gera,R. ; Conway,R.L. ; Viskochil,D. ; Kobori,J.A. ; Rosenberg,A.S. ; Kishnani,P.S.

作者单位： Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT ^[1] Deparment of Pediatrics, Kaiser Permanente, Santa Clara, CA, United States ^[2] Department of Pediatrics, Kaiser Permanente, San Jose, CA, United States ^[3] Department of Pediatrics/Human Development, Michigan State University, East Lansing, MI, United ^[4] Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and ^[5] Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC ^[6]

关键词 antibodies bortezomib enzyme replacement therapy glycogen storage disease type II immune modulation

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交